Skip to main content

Advertisement

SpringerLink
Log in

Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Neuroendocrine tumors are a rare and heterogenous group of neoplasms that arise from hormone-producing cells throughout the body, with the greatest increase in incidence occurring among older adults aged ≥ 65 years. Despite this, there is currently a lack of data regarding the safety and efficacy of systemic treatment for older adults with neuroendocrine tumors. In this review, we provide a synopsis of the current standard-of-care pharmacotherapeutic treatments for neuroendocrine tumors, with an emphasis on available data in older adults. The benefits of various systemic options such as somatostatin analogs, tryptophan hydroxylase inhibition, molecular targeted agents, peptide receptor radionuclide therapy, and chemotherapy were similar between older adults compared to younger patients. However, real-world data regarding tolerance in the older adult population with neuroendocrine tumors are needed. Future development of novel systemic therapies in the neuroendocrine tumor treatment landscape and their inclusion of and potential impact on older adults living with neuroendocrine tumors is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–66.

    Article  PubMed  Google Scholar 

  4. Öberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol. 2012;24(4):282–93.

    Article  Google Scholar 

  5. Lemelin A, Maucort-Boulch D, Castel-Kremer E, Forestier J, Hervieu V, Lorcet M, et al. Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: the LyREMeNET study. Neuroendocrinology. 2020;110(7–8):653–61.

    Article  CAS  PubMed  Google Scholar 

  6. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–38.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):1–13.

    Article  CAS  Google Scholar 

  8. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–52.

    Article  CAS  PubMed  Google Scholar 

  10. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47(Suppl. 2):30–9.

    Article  CAS  PubMed  Google Scholar 

  11. Öberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966–73.

    Article  PubMed  Google Scholar 

  12. Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110(1):35–50.

    Article  CAS  PubMed  Google Scholar 

  13. Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18(1):1–9.

    Article  CAS  Google Scholar 

  14. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600–6.

    Article  CAS  PubMed  Google Scholar 

  15. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.

    Article  CAS  PubMed  Google Scholar 

  16. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  17. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1656–65.

    Article  PubMed  CAS  Google Scholar 

  18. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. Oncologist. 2016;21(3):308–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, et al. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: an observational time and motion analysis. J Oncol Pharm Pract. 2019;25(6):1425–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer. 2019;26(3):145–56.

    Article  Google Scholar 

  21. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.

    Article  PubMed  CAS  Google Scholar 

  22. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh X-MT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–13.

    Article  CAS  PubMed  Google Scholar 

  24. Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D, Hoersch D, et al. Lanreotide in patients with lung neuroendocrine tumors: the randomized double-blind placebo-controlled international phase 3 SPINET Study. J Thorac Oncol. 2017;12(1):S1516–7.

    Article  Google Scholar 

  25. Dasari A, Phan AT, Caplin ME, Pavel ME, Cwikla JB, Raderer M, et al. Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs >65 years: subgroup analyses from the CLARINET study. J Clin Oncol. 2015;33(15_Suppl):15177.

    Article  Google Scholar 

  26. Phan AT, Caplin ME, Pavel ME, Cwikla JB, Raderer M, Sedláčková E, et al. Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: subgroup analyses from the CLARINET study. J Clin Oncol. 2015;33(3_Suppl):367.

    Article  Google Scholar 

  27. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.

    Article  CAS  PubMed  Google Scholar 

  28. Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, et al. TELEPRO: patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world. Oncologist. 2019;24(11):1446–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kulke MH, Kennecke HF, Murali K, Joish VN. Changes in carcinoid syndrome symptoms among patients receiving telotristat ethyl in US clinical practice: findings from the TELEPRO-II real-world study. Cancer Manag Res. 2021;13:7439–46.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cella CA, Minucci S, Spada F, Galdy S, Elgendy M, Ravenda PS, et al. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside. Cancer Treat Rev. 2015;41(9):754–60.

    Article  CAS  PubMed  Google Scholar 

  31. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Scoazec JY. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology. 2013;97(1):45–56.

    Article  CAS  PubMed  Google Scholar 

  33. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol. 2010;65(5):889–93.

    Article  CAS  PubMed  Google Scholar 

  34. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76.

    Article  CAS  PubMed  Google Scholar 

  36. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  CAS  PubMed  Google Scholar 

  37. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.

    Article  CAS  PubMed  Google Scholar 

  39. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017;28(7):1569–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906–13.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421–32.

    Article  CAS  PubMed  Google Scholar 

  42. Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VCG, Neven P, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Ann Oncol. 2016;27(9):1719–25.

    Article  CAS  PubMed  Google Scholar 

  43. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011;366(6):520–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial. Eur Urol. 2012;61(4):826–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

  46. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.

    Article  CAS  PubMed  Google Scholar 

  47. Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. Target Oncol. 2016;11(6):815–24.

    Article  PubMed  Google Scholar 

  48. Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–43.

    Article  CAS  PubMed  Google Scholar 

  49. Brunello A, Basso U, Sacco C, Sava T, De Vivo R, Camerini A, et al. Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol. 2013;24(2):336–42.

    Article  CAS  PubMed  Google Scholar 

  50. Fujita T, Hirayama T, Ishii D, Matsumoto K, Yoshida K, Iwamura M. Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Mol Clin Oncol. 2018;9(4):394–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110(5):1125–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, et al. Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice. Drugs Aging. 2016;33(9):655–63.

    Article  CAS  PubMed  Google Scholar 

  53. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Haider M, Al-Toubah T, El-Haddad G, Strosberg J. Molecular imaging and radionuclide therapy of neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):16–21.

    Article  PubMed  Google Scholar 

  55. Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, et al. Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT. Am J Roentgenol. 2018;211(2):267–77.

    Article  Google Scholar 

  56. Desai H, Borges-Neto S, Wong TZ. Molecular imaging and therapy for neuroendocrine tumors. Curr Treat Options Oncol. 2019;20(10):1–13.

    Article  Google Scholar 

  57. Navalkissoor S, Gnanasegaran G, Baum R. Theranostics and precision medicine special feature. Br J Radiol. 2018;91(1091):20189004.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Turner JH. Recent advances in theranostics and challenges for the future. Br J Radiol. 2018;91(1091):20170893.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752–63.

    Article  CAS  PubMed  Google Scholar 

  62. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Chen L, Navalkissoor S, Quigley A-M, Gnanasegaran G, Mandair D, Toumpanakis C, et al. 177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. Eur J Nucl Med Mol Imaging. 2021;48(11):3582–94.

    Article  PubMed  Google Scholar 

  64. Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, et al. Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients. Cancers. 2021;13(24):6290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303(21):1189–94.

    Article  CAS  PubMed  Google Scholar 

  66. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–75.

    Article  CAS  PubMed  Google Scholar 

  67. Okusaka T, Ueno H, Morizane C, Kondo S, Sakamoto Y, Takahashi H, et al. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22(8):628–33.

    Article  PubMed  Google Scholar 

  68. Cives M, Pelle E, Quaresmini D, Mandriani B, Tucci M, Silvestris F. The role of cytotoxic chemotherapy in well-differentiated gastroenteropancreatic and lung neuroendocrine tumors. Curr Treat Options Oncol. 2019;20(9):72.

    Article  PubMed  Google Scholar 

  69. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–23.

    Article  CAS  PubMed  Google Scholar 

  70. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86(6):944–8.

    Article  CAS  PubMed  Google Scholar 

  71. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004;27(5):485–8.

    Article  CAS  PubMed  Google Scholar 

  72. Weatherstone K, Meyer T. Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Target Oncol. 2012;7(3):161–8.

    Article  PubMed  Google Scholar 

  73. Krug S, Gress TM, Michl P, Rinke A. The role of cytotoxic chemotherapy in advanced pancreatic neuroendocrine tumors. Digestion. 2017;96(2):67–75.

    Article  CAS  PubMed  Google Scholar 

  74. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366–71.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol. 2005;23(16):4216.

    Article  Google Scholar 

  77. Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist. 2020;25(1):e48-52.

    Article  CAS  PubMed  Google Scholar 

  78. Papaxoinis G, Kordatou Z, McCallum L, Nasralla M, Lamarca A, Backen A, et al. Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours. Neuroendocrinology. 2020;110(5):413–21.

    Article  CAS  PubMed  Google Scholar 

  79. Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw. 2022;20(1):29–36.

    Article  CAS  Google Scholar 

  80. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–70.

    Article  CAS  PubMed  Google Scholar 

  81. Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist. 2016;21(6):671–5.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Squires MH, Worth PJ, Konda B, Shah MH, Dillhoff ME, Abdel-Misih S, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas. 2020;49(3):355–60.

    Article  CAS  PubMed  Google Scholar 

  83. de Mestier L, Walter T, Evrard C, de Boissieu P, Hentic O, Cros J, et al. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor. Neuroendocrinology. 2020;110(1–2):83–91.

    Article  PubMed  CAS  Google Scholar 

  84. Chauhan A, Farooqui Z, Murray LA, Weiss HL, War Myint Z, Raajasekar AKA, et al. Capecitabine and temozolomide in neuroendocrine tumor of unknown primary. J Oncol. 2018;2018:3519247.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15):4004.

    Article  Google Scholar 

  86. Feliu J, Escudero P, Llosa F, Bolaños M, Vicent J-M, Yubero A, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J Clin Oncol. 2005;23(13):3104–11.

    Article  CAS  PubMed  Google Scholar 

  87. Stein A, Quidde J, Schröder JK, Göhler T, Tschechne B, Valdix A-R, et al. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer: results from a non-interventional observation study. BMC Cancer. 2016;16(1):82–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P, Biagi JJ, et al. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. Curr Oncol. 2017;24(4):e261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26.

    Article  CAS  PubMed  Google Scholar 

  90. Pérez-Larraya JG, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo J-S, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050–5.

    Article  CAS  Google Scholar 

  91. Al-Toubah T, Morse B, Pelle E, Strosberg J. Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide. Oncologist. 2021;26(2):115–9.

    Article  CAS  PubMed  Google Scholar 

  92. Oziel-Taieb S, Zemmour C, Raoul JL, Mineur L, Poizat F, Charrier N, et al. Efficacy of FOLFOX chemotherapy in metastatic enteropancreatic neuroendocrine tumors. Anticancer Res. 2021;41(4):2071–8.

    Article  CAS  PubMed  Google Scholar 

  93. Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol. 2017;6(1):44–8.

    Article  CAS  PubMed  Google Scholar 

  94. Xu J, Shen L, Bai C, Wang W, Li J, Yu X, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489–99.

    Article  CAS  PubMed  Google Scholar 

  95. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–12.

    Article  CAS  PubMed  Google Scholar 

  96. Chan JA, Faris JE, Murphy JE, Blaszkowsky LS, Kwak EL, McCleary NJ, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol. 2017;35(4):228.

    Article  Google Scholar 

  97. Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT Trial (GETNE1509). J Clin Oncol. 2021;39(20):2304–12.

    Article  CAS  PubMed  Google Scholar 

  98. Pavlakis N, Ransom DT, Wyld D, Sjoquist KM, Asher R, Gebski V, et al. First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) ± capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs). J Clin Oncol. 2020;38(4):604.

    Article  Google Scholar 

  99. Pavlakis N, Ransom DT, Wyld D, Sjoquist KM, Asher R, Gebski V, et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: phase II study evaluating the activity of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM): first results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS). J Clin Oncol. 2020;38(15):4608.

    Article  Google Scholar 

  100. Chauhan A, Kunos C, Khouli RE, Kolesar J, Weiss HL, Carson B, et al. Abstract 674: a phase I trial of Triapine and Lutetium Lu 177 dotatate in combination for well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cancer Res. 2021;81(13 Suppl.):674.

    Article  Google Scholar 

  101. Kunikowska J, Królicki L. Targeted α-emitter therapy of neuroendocrine tumors. Semin Nucl Med. 2020;50(2):171–6.

    Article  PubMed  Google Scholar 

  102. Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with (225)actinium and (213)bismuth. Curr Radiopharm. 2018;11(3):200–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Yadav MP, Ballal S, Sahoo RK, Bal C. Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2021;2021:1–12.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA

    Christiana Crook, Ya-Han Zhang & Daneng Li

Authors
  1. Christiana Crook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-Han Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daneng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daneng Li.

Ethics declarations

Funding

No external funding was used in the preparation of this article.

Conflicts of Interest/Competing Interests

Daneng Li reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer, Coherus, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon, Merck, MiNA Therapeutics, QED, Servier, Sun Pharma, Taiho, and TerSera Therapeutics, all outside the submitted work. Christiana Crook and Ya-Han Zhang declare that they have no conflicts of interest that might be relevant to the contents of this article.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Code availability

Not applicable.

Authors’ Contributions

Christiana Crook and Daneng Li conceived the idea for this article. Christiana Crook performed the literature search and data analysis. All authors drafted and/or critically revised the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crook, C., Zhang, YH. & Li, D. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs Aging 39, 257–269 (2022). https://doi.org/10.1007/s40266-022-00934-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-022-00934-1

Search

Navigation